Centessa Pharmaceuticals — Technical Presentation (December 2022)
15 slides from Centessa Pharmaceuticals's technical presentation, Dec 12, 2022
Slide 1: SerpinPC in persons with severe hemophilia: long-term treatment from a first-in-human study
SerpinPC in persons with severe hemophilia (PwH): long-term treatment from a multi- center, multi-part, first-in-human study T Baglin*, A Koch, I Mocanu+, L Makhaldiani$, J Huntington* *Centessa Pharmaceuticals plc, 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT, Simbec-Orion Clinic
Slide 2: This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes
This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv
Slide 3: SerpinPC: a subcutaneously administered biologic inhibitor of APC
SerpinPC: a subcutaneously administered biologic inhibitor of APC 3 • Unprecedented biology with novel pharmacology • Intended for subcutaneous prophylaxis across hemophilia subtypes • Modified a1 anti-trypsin with 3 substitution mutations to confer selective inhibition of activated protein C (APC)
Slide 4: SerpinPC and thrombin generation
SerpinPC and thrombin generation 4 Extrinsic Tenase Intrinsic Tenase Prothrombinase Prothrombin Thrombin SerpinPC APC Protein C
Slide 5: AP-0101 study design: adaptive first-in-human study of SerpinPC
1.2 mpk Q2W AP-0101 study design: adaptive first-in-human study to investigate the safety, tolerability, efficacy and PK of SerpinPC 5 60 mg Q4W Part 2 MAD PwH (n=23) Part 3 OLE at flat dose (n=22) Part 4 OLE at 1.2 mpk Q2W (n=21) Part 1b SAD PwH (n=12) Week 1 to 24 Week 25 to 72 Week 73 to 96Timing
Slide 6: AP-0101 Parts 2-4: demographics, baseline characteristics and early terminations
AP-0101 Parts 2-4: demographics, baseline characteristics and early terminations 6 * “Target joint” = joint with >3 bleeds in any 6-month period ** Determined by Safety Review Group Characteristic Value Age, median (min to max) 39 (21 to 56) Number of subjects 23 (including 12 from Part 1b SAD) Pros
Slide 7: AP-0101 Parts 3 and 4: no observations of treatment-related adverse events
AP-0101 Parts 3 and 4: no observations of treatment-related adverse events 7* Determined by Safety Review Group Part 3 (n=22) Part 4 (n=21) Treatment Emergent Adverse Events Subjects with event No. (%) Treatment-related* Subjects with event No. (%) Treatment-related* Elevated ALT 3 (14%) 0 3 (14%) 0
Slide 8: AP-0101 Parts 3 and 4: no treatment-related, non-transient elevations in D-dimer
AP-0101 Parts 3 and 4: no observations of treatment-related, non-transient elevations in D-dimer 8 * For Part 3, one subject with rectosigmoid cancer and one subject with traumatic hip bleed **For Part 4, one subject with rectosigmoid cancer Result Subjects in Part 3 (n=22) No. (%) Subjects in Part
Slide 9: AP-0101: Anti-drug Antibodies (ADAs) and Pharmacokinetics (PK)
AP-0101: Anti-drug Antibodies (ADAs) and Pharmacokinetics (PK) 9 • Samples for ADA characterization including neutralizing capacity and cross-reactivity ongoing • PK analysis ongoing, including exposure-response modeling
Slide 10: AP-0101 Parts 3 and 4: reduction in Annualized Bleed Rate (ABR)
AP-0101 Parts 3 and 4: reduction in Annualized Bleed Rate (ABR) 10 Part Median ABR from prospective baseline Median ABR observed in this part Median % change from baseline Part 3 (n=22) 34.1 6.2 -83% Part 4 (n=21) 35.5 2.2 -93% Part Median ABR from prospective baseline Median ABR observed in this pa
Slide 11: AP-0101 Part 3: ABR at 60mg Q4W flat dose
11 HemA HemB AP-0101 Part 3: ABR at 60mg Q4W flat dose All bleeds ABR Spontaneous joint bleeds ABR Medians Part 3 48 weeks of treatment Baseline -60 -40 -20 0 20 40 60 ABR 4.327.5Medians Baseline Part 3 48 weeks of treatment -60 -40 -20 0 20 40 60 ABR 6.234.1
Slide 12: AP-0101 Part 4: ABR at 1.2 mpk Q2W
12 HemA HemB AP-0101 Part 4: ABR at 1.2 mpk Q2W -60 -40 -20 0 20 40 60 2.2 28.3 2.2 -60 -40 -20 0 20 40 60 ABR ABR All bleeds ABR Spontaneous joint bleeds ABR Baseline Part 4 24 weeks of treatment Part 4 24 weeks of treatment Baseline 35.5Medians Medians
Slide 13: AP-0101: All bleed median ABR by dose level
AP-0101: All bleed median ABR by dose level 13 8.6 8.8 6.2 4.4 2.2 0.3 0.6 ~0.8 1.2 2.4 Effective monthly dose (mpk) * 60 mg Flat dose which was equivalent to ~0.8 mpk * n=7n=7 n=8 n=22 n=21 Part 2 Part 2Part 2 Part 3 Part 4
Slide 14: Summary
Summary 14 • SerpinPC – Novel MoA: inhibition of APC to rebalance coagulation – Broad potential to treat all subtypes of hemophilia – Subcutaneous route of administration • Results of Phase 2, Parts 3 and 4 – No observations of treatment-related adverse events – No observations of treatment-related
Slide 15: Thank you to all the persons who participate in this study
15 Thank you to all the persons who have and continue to participate in this study
Centessa Pharmaceuticals — Technical Presentation (December 2022) on 6ix